Paul Bonanos

ARTICLE | Deals Still heavily reliant on cystic fibrosis drugs, Vertex sees $5B peak potential in pair of endocrinology assets By Paul Bonanos, Director of Biopharma Intelligence Vertex believes its $10 billion acquisition of Crinetics will give it a pair of growth drivers that can further diversify the company, easing its reliance on a cystic fibrosis franchise that may be near its ceiling.

ARTICLE | Deals Swiss pharma acquires preclinical U.K. company with novel payloads, rewarding syndicate of early-stage VCs By Paul Bonanos, Director of Biopharma Intelligence Novartis’ planned acquisition of Myricx for $1.1 billion up front would give it a platform to develop ADCs with a novel payload, broadening its commitment to conjugated cancer treatments beyond its historical strengths in radioligand therapies and small molecules.

ARTICLE | Finance Plus: Abivax’s upsized follow-on, BridgeBio draws cash to support launches, and more By Paul Bonanos, Director of Biopharma Intelligence, and Lindsay Martin, Biopharma Analyst Nearly a year after PureTech established spin-out company Celea and said it would seek outside investors to back its IPF program, an investor syndicate has signed on for a $180 million series A. The group backing  Celea Therapeutics Inc.